Avalo Therapeutics Files 8-K
Ticker: AVTX · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-event
Related Tickers: AVTX
TL;DR
AVTX filed an 8-K, but it's light on details. Watch for follow-up.
AI Summary
Avalo Therapeutics, Inc. filed an 8-K on December 2, 2025, reporting an "Other Events" item. The company, formerly known as Cerecor Inc. until November 2, 2011, is incorporated in Delaware and headquartered in Wayne, Pennsylvania. This filing does not contain specific financial figures or details about the nature of the 'Other Events'.
Why It Matters
This filing indicates a corporate event has occurred, but without further details, its immediate impact on investors or the company's operations is unclear.
Risk Assessment
Risk Level: low — The filing is a standard procedural document without immediate financial or operational disclosures that would indicate a change in risk.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former company name
- December 2, 2025 (date) — Date of report
- Wayne, Pennsylvania (location) — Principal executive offices
FAQ
What specific event is reported under 'Other Events' in this 8-K filing?
The filing does not specify the nature of the 'Other Events'.
When was Avalo Therapeutics, Inc. formerly known as Cerecor Inc.?
The company changed its name from Cerecor Inc. on November 2, 2011.
What is the principal executive office address for Avalo Therapeutics, Inc.?
The principal executive offices are located at 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087.
What is the IRS Employer Identification Number for Avalo Therapeutics, Inc.?
The IRS Employer Identification Number is 45-0705648.
What is the SIC code for Avalo Therapeutics, Inc.?
The Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
Filing Stats: 420 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2025-12-02 06:38:13
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
Filing Documents
- avtx-20251202.htm (8-K) — 25KB
- ex-991_dec2025xavalocorp.htm (EX-99.1) — 28KB
- ex-991_dec2025xavalocorp001.jpg (GRAPHIC) — 116KB
- ex-991_dec2025xavalocorp002.jpg (GRAPHIC) — 233KB
- ex-991_dec2025xavalocorp003.jpg (GRAPHIC) — 163KB
- ex-991_dec2025xavalocorp004.jpg (GRAPHIC) — 128KB
- ex-991_dec2025xavalocorp005.jpg (GRAPHIC) — 76KB
- ex-991_dec2025xavalocorp006.jpg (GRAPHIC) — 112KB
- ex-991_dec2025xavalocorp007.jpg (GRAPHIC) — 95KB
- ex-991_dec2025xavalocorp008.jpg (GRAPHIC) — 124KB
- ex-991_dec2025xavalocorp009.jpg (GRAPHIC) — 132KB
- ex-991_dec2025xavalocorp010.jpg (GRAPHIC) — 107KB
- ex-991_dec2025xavalocorp011.jpg (GRAPHIC) — 110KB
- ex-991_dec2025xavalocorp012.jpg (GRAPHIC) — 152KB
- ex-991_dec2025xavalocorp013.jpg (GRAPHIC) — 141KB
- ex-991_dec2025xavalocorp014.jpg (GRAPHIC) — 122KB
- ex-991_dec2025xavalocorp015.jpg (GRAPHIC) — 148KB
- ex-991_dec2025xavalocorp016.jpg (GRAPHIC) — 69KB
- ex-991_dec2025xavalocorp017.jpg (GRAPHIC) — 191KB
- ex-991_dec2025xavalocorp018.jpg (GRAPHIC) — 135KB
- ex-991_dec2025xavalocorp019.jpg (GRAPHIC) — 51KB
- ex-991_dec2025xavalocorp020.jpg (GRAPHIC) — 43KB
- ex-991_dec2025xavalocorp021.jpg (GRAPHIC) — 88KB
- 0001534120-25-000022.txt ( ) — 3695KB
- avtx-20251202.xsd (EX-101.SCH) — 2KB
- avtx-20251202_def.xml (EX-101.DEF) — 14KB
- avtx-20251202_lab.xml (EX-101.LAB) — 24KB
- avtx-20251202_pre.xml (EX-101.PRE) — 15KB
- avtx-20251202_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 2, 2025, Avalo Therapeutics, Inc. posted on its website an updated investor presentation (the "Investor Presentation"). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Investor Presentation. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: December 2, 2025 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2